Physician profile
Daniel J Verina
NPI 1083929897
$463,989.20
in general payments reported to CMS, 2019-2025
26 companies · $74K in 2025
The $74K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69K · 2022: $121K · 2023: $85K · 2024: $116K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $176K · Travel and Lodging: $64K · Food and Beverage: $15K · Consulting Fee: $13K · Honoraria: $4,370 · Grant: $1,925 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $250 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $175,765.25 |
| Travel and Lodging | $63,721.25 |
| Food and Beverage | $14,939.23 |
| Consulting Fee | $12,718.25 |
| Honoraria | $4,370.00 |
| Grant | $1,925.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $250.00 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $249,821.90 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Genzyme Corporation | $66,942.10 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60,786.67 | 2021-2025 | Ninlaro |
| Glaxosmithkline, LLC. | $28,727.29 | 2021-2025 | Blenrep |
| Karyopharm Therapeutics INC. | $25,640.16 | 2021-2025 | Xpovio |
| Adaptive Biotechnologies Corporation | $11,313.33 | 2022-2025 | Clonoseq |
| E.R. Squibb & Sons, L.L.C. | $6,605.05 | 2021-2023 | Reblozyl |
| Amgen INC. | $5,872.29 | 2021-2023 | Kyprolis |
| Celgene Corporation | $4,154.17 | 2021-2024 | Pomalyst |
| Pfizer INC. | $1,543.67 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $1,071.73 | 2023-2025 | Tecvayli, Carvykti, Darzalex |
| Legend Biotech USA INC. | $540.62 | 2022-2025 | Carvykti |
| Kite Pharma, INC. | $230.23 | 2025 | |
| Beigene USA, INC. | $125.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $122.44 | 2022 | |
| Merck Sharp & Dohme LLC | $97.73 | 2021-2025 | Keytruda, Welireg |
| Genmab U.S., INC. | $93.06 | 2023 | Epkinly |
| Emd Serono, INC. | $30.59 | 2024 | |
| Rigel Pharmaceuticals, INC. | $25.90 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Abbvie INC. | $25.28 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.39 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.32 | 2024 | |
| Genentech USA, INC. | $17.12 | 2023 | Venclexta |
| Seagen INC. | $16.43 | 2021 | |
| Servier Pharmaceuticals LLC | $15.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Verina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.